Nexplanon

ETONOGESTREL

Manufacturer: Organon LLC

Score: 141.0

Quick Summary

Nexplanon is a radiopaque, progestin-only, soft, flexible implant used for contraception in women. It is inserted subdermally and releases etonogestrel, which prevents pregnancy by suppressing ovulation, increasing cervical mucus viscosity, and altering the endometrium. The implant is effective for up to 3 years and should be removed by the end of the third year. Important safety information includes contraindications such as known or suspected pregnancy, thrombosis, liver tumors, and undiagnosed abnormal genital bleeding. Adverse reactions may include change in menstrual bleeding patterns, headache, vaginitis, weight increase, acne, breast pain, and abdominal pain. The main dosing recommendation is to insert one implant subdermally, and special population considerations include use during pregnancy, pediatric use, and geriatric use.

Key Clinical Findings and Indications

Contraception in women
Suppression of ovulation
Increase in cervical mucus viscosity
Alteration of the endometrium

Important Safety Information

Warning

Nexplanon should not be used in women with known or suspected pregnancy, thrombosis, liver tumors, or undiagnosed abnormal genital bleeding.

Contraindications

Known or suspected pregnancy
Current or past history of thrombosis or thromboembolic disorders
Liver tumors, benign or malignant, or active liver disease
Undiagnosed abnormal genital bleeding
Known or suspected breast cancer, personal history of breast cancer, or other progestin-sensitive cancer, now or in the past
Allergic reaction to any of the components of Nexplanon

Adverse Reactions

Change in menstrual bleeding patterns
Headache
Vaginitis
Weight increase
Acne
Breast pain
Abdominal pain
Pharyngitis

Dosing Recommendations

General Guidance

No dose adjustments necessary

Contraception

Adult Dose

One implant inserted subdermally

Pediatric Dose

Not applicable

Special Population Considerations

Pregnancy

Nexplanon is contraindicated during pregnancy
Etonogestrel blood level determination can be used for verification of the presence of the implant

Nursing Mothers

Nexplanon should not be used in breastfeeding women until after the fourth postpartum week

Pediatric Use

Safety and efficacy of Nexplanon have been established in women of reproductive age
Use of this product before menarche is not indicated

Geriatric Use

This product has not been studied in women over 65 years of age and is not indicated in this population

Similar Drugs

Norelgestromin and Ethinly Estradiol

NORELGESTROMIN AND ETHINLY ESTRADIOL

Amneal Pharmaceuticals NY LLC

Similarity: 61.5%